CD99L2 Antibodies

CD99 antigen-like protein 2 (CD99L2)

Plays a role in a late step of leukocyte extravasation assisting cells to conquer the endothelial basement membrane. Acts at exactly the same site as, but independently of, PECAM1 (By similarity).

Homophilic adhesion molecule, but these interactions might not be required for cell aggregation (By similarity). .

Gene Information

Human
Gene Name:	CD99L2
Uniprot:	Q8TCZ2
Entrez:	83692

Family

Belongs to:
CD99 family

Alternative Names

CD99 antigen; CD99 antigen-like 2; CD99 antigen-like protein 2; CD99 molecule-like 2; CD99B; CD99L2; CD99-L2; DKFZp761H2024; MIC2 like 1; MIC2L1; MIC2-like protein 1

Molecular Weight

Mass (kDA):
27.986 kDA

Genomic Context

Human
Location:	Xq28
Sequence:	X; NC_000023.11 (150766336..150898816, complement)

Tissue Specificity

Expressed in many tissues, with low expression in thymus.

Subcellular Localizations

Cell membrane; Single-pass type I membrane protein; Extracellular side. Cell junction.

Diseases

• Extravasation
• Inflammation
• Tissue Adhesions
• Autistic Disorder
• Nervousness
• Chromosomal Translocation
• Autism Spectrum Disorders

• Inflammatory Response

Interacting Proteins

• SGTA
• SGTB
• UBQLN1

Pathways

• Diapedesis
• Male Meiosis
• Neutrophil Extravasation
• Meiosis
• Inflammatory Response

PTMs

• Glycoprotein

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CD99L2

Boster Bio: Best Uses Of The CD99L2 Marker

You've come to the right spot if you're looking for information on Boster bio: Best Uses For The Cell Death Protein-2 Marker. This article discusses important issues surrounding CD99L2, such as Spectrin repeat-containing nuclear envelope protein 1, Schizophrenia and Cystic urticaria.

Spectrin repeat-containing nuclear envelope protein 1

The CD99L2 marker can be used for immunohistochemical staining of a variety cells. It is versatile and highly specific. This marker has a long and successful history. It was developed by Steven Boster (biotechnologist). In 1993, Boster developed his first product, which earned him the nickname "he who converts science in the lavatory." He quickly developed hundreds of primary antibodies for various uses, including IHC, and became the largest antibody catalog in China by the late 90s. Boster Bio created PicoKineTMTMTM, a patented ELISA platform. This allows for high-sensitivity ELISA tests.

Activity-dependent neuroprotector

ADNP, or activitydependent neuroprotector is an enzyme that protects neurons NMDA toxicity. ADNP also regulates neuronal cell cycle. It is a widely-dispersed protein with a high affinity towards the hippocampus. Although NMDA-induced toxicity can be caused by other compounds ADNP is not a neurotoxicant.

ADNP, or activity-dependent neuroprotector, is a molecule that contains an eight-amino acid peptide. This protein is essential for neuroprotective effects. Its inhibition could be beneficial in MS patients. ADNP expression was evaluated in peripheral blood mononuclear cell lines from MS patients and healthy donors. To detect ADNP's mRNA, antibodies against ADNP were used. Its effects on the proliferation of immune cells were also determined.

Cystic urticaria

Studies have shown a correlation of the CD99L2 marker with cystic urticaria. It is a 23-35 kDa protein that is expressed in mast cells. It induces the release by mast cells of histamine, IL-3 and IFN-g. Although urticaria has been linked to the expression of this protein, there are no evidence that it is responsible.

Chronic hives, also known as urticaria, is a condition that causes itching, redness, and inflammation for up to six weeks. Although the cause of chronic hives is not well understood, it is thought that around half of patients have antibodies that attack the mast cells and trigger the release chemical chemicals like histamine. These hives are rarely cured by treating the underlying autoimmune condition, but treatments for chronic hives are available. Most patients will experience a gradual remission and their CD99L2 marker will fade in time.

CSU can be diagnosed by autoantibodies against CD99L2 markers. These antibodies may target mast cells and basophils. These immune cells produce polymononuclear cell-producing cells and are the main cause of CSU. CSU is rare, but skin biopsies may be necessary for patients with other inflammatory conditions.

The study also suggests that chronic urticaria patients may be affected by a circulating mediator. The search for a circulating facilitator has been ongoing for more than 30 years. Over the years, many theories have been proposed, including an autoimmune explanation. A recent study revealed that women with CSU are 23 times more likely than women without the disorder to develop hypothyroidism.

Schizophrenia

Boster Bio Anti CD99 Antigen Like Protein 2 CD99L2 Antibody reacts against Human, Mouse, Rat. It was created by Steven Boster, also known as "he that converts science in a lavatory". Since its inception, Boster has been the leading catalog antibody company in China. The company uses proprietary trade secrets to develop high-sensitivity ELISA kits.

Timothy syndrome

CD99L2 is a genetic marker for the condition known as Timothy syndrome. This disorder presents with a range of symptoms that affect the heart and nervous system as well as physical appearance. The severity of symptoms can vary widely, from mild to severe. Both males, and females, may experience symptoms. The CD99L2 marker is useful for determining whether a child has the syndrome and guiding treatment.

The CaCNA1C gene is responsible for the regulation of several genes during fetal development. Mutations in the CaCNA1C gene could cause severe arrhythmias or affect the E–C coupling of some body systems. This gene is important because it controls the activity of calcium channels in the heart. Any of these symptoms could result from a CaCNA1C mutation.

LQTS (long QT syndrome) is another genetic cause for Timothy syndrome. Although both types of LQTS look very similar, the causes are completely distinct. All LQTS suffer from abnormal heart rhythms and can result in cardiac arrest or fainting. This condition can develop in middle-aged or early childhood. The condition is usually non-syndromic and affects the brain. Timothy syndrome can often present in early adulthood with severe neurodevelopmental problems.

TS can easily be diagnosed early in life with cardiac arrhythmias, prolonged QT intervals on EKG, or other signs. Fetal bradycardia, or cardiac malformations could also be signs of TS. Children with the condition may also exhibit facial abnormalities. Other symptoms that could indicate the existence of the syndrome include recurrent infections and paroxysmal hypoglycemic episodes. Seizures and intellectual disability are also possible. It is necessary to confirm the diagnosis by genetic testing for mutations of the CACNA1C genome.